Protecting Bone from Radiation Damage
Targeting the HIF-2 Signaling Pathway as a Radioprotective Strategy for Bone
This research looks for new ways to protect bones from damage caused by radiation therapy in cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11125761 on NIH RePORTER |
What this research studies
Many cancer patients receive radiation therapy, which can unfortunately weaken bones and increase the risk of fractures in healthy areas. Current treatments like bisphosphonates don't fully solve this problem for patients. Our team is exploring how a natural process called HIF-2, which helps cells survive in low-oxygen conditions, might be used to shield bone from radiation. We believe understanding and targeting HIF-2 could lead to better ways to keep bones strong during cancer treatment.
Who could benefit from this research
Good fit: Patients who have received or are scheduled to receive radiation therapy for cancer, especially those at risk for bone damage, are the focus of this research.
Not a fit: Patients who have not undergone radiation therapy or do not have concerns about bone health related to radiation may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that prevent bone fractures in cancer patients undergoing radiation therapy.
How similar studies have performed: This approach is exploring a novel mechanism, as the contribution of hypoxia/HIF signaling during radiation-induced bone damage has not been well defined, though preliminary data supports the direction.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Wu, Colleen — Duke University
- Study coordinator: Wu, Colleen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.